Segment Information (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Jun. 30, 2022
USD ($)
|
Mar. 31, 2022
USD ($)
|
Jun. 30, 2021
USD ($)
|
Mar. 31, 2021
USD ($)
|
Jun. 30, 2022
USD ($)
segment
|
Jun. 30, 2021
USD ($)
|
|
| Segment Reporting [Abstract] | ||||||
| Number of operating segments | segment | 2 | |||||
| Segment Reporting Information [Line Items] | ||||||
| Total Revenue | $ 125,072 | $ 121,724 | $ 242,241 | $ 237,257 | ||
| COST OF REVENUE | 81,126 | 68,734 | 160,063 | 142,693 | ||
| GROSS PROFIT | 43,946 | 52,990 | 82,178 | 94,564 | ||
| General and administrative | 57,951 | 54,638 | 124,199 | 95,114 | ||
| Research and development | 8,626 | 3,495 | 16,339 | 5,951 | ||
| Sales and marketing | 17,071 | 17,224 | 33,370 | 30,973 | ||
| Total operating expenses | 83,648 | 75,357 | 173,908 | 132,038 | ||
| Loss from operations | (39,702) | (22,367) | (91,730) | (37,474) | ||
| Interest expense, net | 926 | 902 | 2,227 | 2,079 | ||
| Other expense (income), net | 405 | (171) | 237 | (341) | ||
| Gain on investment in and loan receivable from non-consolidated affiliate, net | 0 | (96,534) | 0 | (91,510) | ||
| (Loss) income before taxes | (41,033) | 73,436 | (94,194) | 52,298 | ||
| Income tax benefit | (5,730) | (2,437) | (9,483) | (1,461) | ||
| NET (LOSS) INCOME | (35,303) | $ (49,408) | 75,873 | $ (22,114) | (84,711) | 53,759 |
| Clinical Services | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Total Revenue | 105,635 | 101,405 | 204,426 | 197,892 | ||
| COST OF REVENUE | 67,035 | 57,233 | 132,302 | 118,798 | ||
| GROSS PROFIT | 38,600 | 44,172 | 72,124 | 79,094 | ||
| Amortization of acquired intangible assets | 4,300 | 700 | 8,500 | 700 | ||
| Clinical Services | COVID-19 PCR Testing | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Write off of COVID-19 PCR testing inventory | 5,300 | |||||
| Pharma Services | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Total Revenue | 19,437 | 20,319 | 37,815 | 39,365 | ||
| COST OF REVENUE | 14,091 | 11,501 | 27,761 | 23,895 | ||
| GROSS PROFIT | 5,346 | $ 8,818 | 10,054 | $ 15,470 | ||
| Amortization of acquired intangible assets | $ 600 | $ 0 | $ 1,200 | |||
| X | ||||||||||
- Definition Intangible Assets Acquired, Amortization Expense No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|